DADC
AVXL icon

D.A. Davidson & Co’s Anavex Life Sciences AVXL Stock Holding History

D.A. Davidson & Co’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,335
Closed -$88.7K – 1449
2025
Q1 		$88.7K Sell
10,335
-1,050
-9% -$9.91K ﹤0.01% 1369
2024
Q4 		$122K Buy
+11,385
New +$87.6K ﹤0.01% 1371
2024
Q2 		– Sell
-13,770
Closed -$70.1K – 1372
2024
Q1 		$70.1K Buy
13,770
+2,520
+22% +$14.2K ﹤0.01% 1352
2023
Q4 		$105K Buy
+11,250
New +$77.4K ﹤0.01% 1321

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

D.A. Davidson & Co's AVXL Position: Q2 2025 in Review

D.A. Davidson & Co sold out of Anavex Life Sciences (AVXL) in Q2 2025, closing a stake of 10,335 shares — an estimated $88.7K sold.

D.A. Davidson & Co first reported a position in AVXL in Q4 2023 and held it in 4 quarters. The position peaked at $122K in Q4 2024. 178 funds tracked by Wall St. Rank hold AVXL as of Q2 2025.

  • D.A. Davidson & Co reported no remaining Anavex Life Sciences position as of Q2 2025 after selling out during the quarter.
  • D.A. Davidson & Co sold 10,335 Anavex Life Sciences shares in Q2 2025, an estimated $88.7K.
  • D.A. Davidson & Co first reported a position in Anavex Life Sciences in Q4 2023 and held it in 4 quarters.
  • D.A. Davidson & Co's Anavex Life Sciences position peaked at $122K in Q4 2024.
  • 178 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2025.

Based on D.A. Davidson & Co's 13F filing for Q2 2025, filed 30 Jul 2025.